-
Gene Cradle Initiates First Regulatory Gene Therapy Study in China for Late-Onset Pompe Disease
•
Gene Cradle, a Beijing-based gene therapy specialist, has achieved a milestone by administering its GC301 to the first patient with late-onset Pompe disease (LOPD) in a regulatory study in China. This marks the nation’s first patient dosing of an adeno-associated virus (AAV) gene therapy for LOPD. GC301 is an innovative…
-
Phase I Success for Shandong Xinhua’s OAB-14, Advancing to Phase IIa in Alzheimer’s Therapy
•
Shandong Xinhua Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Shenzhen (SHE: 000756), has declared the successful completion of a Phase I clinical trial for its OAB-14 drug candidate in a dry suspension formulation. Following the positive outcome, the company is now gearing up to initiate a Phase IIa…
-
Jiangsu Hengrui Medicine Co., Ltd Announces Resignations of Two Deputy General Managers
•
Jiangsu Hengrui Medicine Co., Ltd, a leading pharmaceutical company based in China and listed on the Shanghai Stock Exchange (SHA: 600276), has announced the resignation of two of its key executives, Ms. Jiang Sumei and Mr. Wang Hongsen, both of whom held the position of Deputy General Manager. Both executives…
-
Hunan Warrant Pharmaceutical’s ZG-002 Receives NMPA Approval for Clinical Trials in Plaque Psoriasis
•
Hunan Warrant Pharmaceutical Co., Ltd, a pharmaceutical company based in China and listed on the Shanghai Stock Exchange’s Science and Technology Innovation Board (SHA: 688799), has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug candidate, ZG-002. This new molecule is intended for…
-
Allgens Medical Technology’s BonGold Receives Marketing Approval from Malaysia’s MDA
•
Allgens Medical Technology Co., Ltd, a Beijing-based innovator in regenerative medicine materials and implantable devices listed on the Shanghai Stock Exchange (SHA: 688613), has secured marketing approval from the Medical Device Authority (MDA) of Malaysia for its flagship product, BonGold, an artificial bone repair material. BonGold is a biomimetic mineralized…
-
Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights
•
Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1477), has declared its intent to proceed with a share repurchase program, targeting 10% of the total issued shares, excluding treasury shares. This initiative, which is not to exceed HKD 200 million, is…
-
Novartis and Versant Ventures Launch Borealis Biosciences with a Focus on RNA Medicines for Kidney Diseases
•
Novartis (NYSE: NVS), a Swiss pharmaceutical heavyweight, has joined forces with the US venture capital fund Versant Ventures to launch Borealis Biosciences, a cutting-edge biotech firm dedicated to pioneering next-generation RNA medicines for kidney diseases. Borealis emerges from incubation with a substantial USD 150 million in Series A financing, bolstered…
-
UK MHRA Approves Eisai and Biogen’s Alzheimer’s Drug Leqembi, Despite NICE Reimbursement Rejection
•
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Leqembi (lecanemab), a co-developed Alzheimer’s disease drug by Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB). This development, however, was met with a refusal from the National Institute for Health and Clinical Excellence (NICE), the…
